For the distinction between renal cell carcinomas and urothelial carcinomas, sensitivity was 86.7% and specificity 91.3% for PAX8, while sensitivity was 82.7% and specificity 99.8% for CDH16. The gene discussed is PAX8; the disease is renal cell carcinoma.